Genzyme Corporation Updated Company Profile : Outlook, Strategy and Forecasts

NEW YORK--(Business Wire)--Reportlinker.com announces that a new market research report
related to the Pharmaceutical industry is available in its catalogue.

Genzyme Corporation: Company Profile

To order that report:

www.reportlinker.com/p073698
/Genzyme-Corporation-Company-Profile.html

(Due to its length, this URL may need to be copied/pasted into
your Internet browser's address field. Remove the extra space if one
exists.)

For more information, contact Nicolas by email
nbo@reportlinker.com , by phone +33 4 37 65 17 03.

This analysis examines the historical and forecast performance for
Genzyme in the ethical pharmaceutical sector. The profile encompasses
global company strategy, portfolio and pipeline analysis and
assessment of financial performance, with 1-6 year sales forecasts for
key drugs. An interactive forecasting and analysis tool provides
continually updated quantitative and qualitative information.

Benchmark Genzyme's performance against key rivals in the ethical
pharmaceutical sector. Analyze how an anticipated increase in
competition for the Gaucher's treatment Cerezyme will drive
therapeutic diversification. Assess the company's steady expansion of
revenues generated via the oncology market

CHAPTER 1 EXECUTIVE SUMMARY 2

Key findings 2

Historical and forecast ethical sales performance 3

Therapeutic strategy 5

Therapeutic strategy 5

Launch and expiry outlook 8

Externalization, geographic and molecule type strategies 11

Externalization strategy 12

Geographic strategy 13

Molecule type strategy 13

SWOT analysis 15

Strengths 15

Weaknesses 16

Opportunities 17

Threats 17

CHAPTER 2 CORPORATE HISTORY 22

Key findings 22

Background 23

Key corporate developments 24

M&A history 25

M&A history 25

ILEX Oncology 26

Bone Care International 26

AnorMED acquisition 27

Mozobil-the catalyst 27

Bioenvision 28

Current corporate structure 29

Biotherapeutics 29

Lysosomal storage disorders 30

Genetics/diagnostics 31

Current management team 32

CHAPTER 3 HISTORICAL PERFORMANCE 33

Key findings 33

Introduction 34

Revenue and growth rate analysis, 2001-06 34

Revenue and growth rate vs. peer set 35

Product analysis, 2001-06 39

Product analysis, 2001-06 39

Growth drivers 39

Cerezyme 39

Fabrazyme 40

Renagel 40

Synvisc 40

Operating revenue and cost analysis, 2001-06 41

Operating revenue/cost analysis 43

CHAPTER 4 FORECAST PERFORMANCE 45

Key findings 45

Introduction 46

Revenue and growth rate, 2006-12 46

Product analysis, 2006-12 47

Growth drivers 51

Myozyme 51

Renagel/Renvela 52

Clolar 52

Fabrazyme 52

Synvisc 52

Therapy area analysis, 2006-12 54

Endocrine, metabolic and genetic disorders 57

Cardiovascular & hematology 57

Oncology 58

Therapy area focus 59

Launches and expiries analysis, 2006-12 62

Launch portfolio 62

Expiry portfolio 65

Launch/core/expiry configuration 67

Externalization analysis, 2006-12 70

Geographic analysis, 2006-12 75

Geographic analysis, 2006-12 75

Molecule type analysis, 2006-12 79

Molecule type analysis, 2006-12 79

CHAPTER 5 KEY PRODUCTS AND COMPETITORS 84

Key findings 84

Overview 85

Endocrine, metabolic & genetic disorders 86

Cerezyme 86

Overview 86

Sales forecast 87

Newsflow 87

Competitive landscape 88

Fabrazyme 91

Overview 91

Sales forecast 92

Newsflow 92

Competitive landscape 93

Myozyme 95

Overview 95

Sales forecast 96

Newsflow 96

Competitive landscape 96

Cardiovascular & hematology 99

Renagel/Renvela 99

Overview 99

Sales forecast 100

Newsflow 100

Competitive landscape 101

Oncology 104

Clolar 104

Overview 104

Sales forecast 105

Newsflow 105

R&D pipeline 108

CHAPTER 6 APPENDIX 109

IMS vs. company-reported data reconciliation 109

References 109

Datamonitor Reports 109

Abbreviations 110

List of Tables

Table 1: Genzyme Group Corporate Executive Committee 32

Table 2: Peer set overview 35

Table 3: Operating revenue/cost analysis ($m), 2001-06 41

Table 4: Operating cost ratio analysis (% of total revenues),
2001-06 43

Table 5: Product portfolio overview, sales ($m), 2006-12 48

Table 6: Therapy area overview, sales ($m), 2006-12 54

Table 7: Launch portfolio overview, sales ($m), 2006-12 62

Table 8: Core portfolio overview, sales ($m), 2006-12 64

Table 9: Expiry portfolio overview, sales ($m), 2006-12 65

Table 10: Externally developed portfolio ($m), 2006-12 70

Table 11: Molecule type overview, sales ($m), 2006-12 79

Table 12: Key products overview 85

Table 13: Cerezyme: overview 86

Table 14: Cerezyme: sales forecast ($m), 2006-12 87

Table 15: Cerezyme: newsflow 87

Table 16: Fabrazyme: overview 91

Table 17: Fabrazyme: sales forecast ($m), 2006-12 92

Table 18: Fabrazyme: newsflow 92

Table 19: Myozyme: overview 95

Table 20: Myozyme: sales forecast ($m), 2006-12 96

Table 21: Myozyme: newsflow 96

Table 22: Renagel/Renvela: overview 99

Table 23: Renagel/Renvela: sales forecast ($m), 2006-12 100

Table 24: Renagel/Renvela: newsflow 100

Table 25: Clolar: overview 104

Table 26: Clolar: sales forecast ($m), 2006-12 105

Table 27: Clolar: newsflow 105

Table 28: Genzyme's R&D pipeline (Phase I-registration) 108

List of Figures

Figure 1: Historical and forecast ethical sales performance (%
CAGR), Genzyme and biotechnology peer set 3

Figure 2: Therapeutic focus vs. biotechnology peer set (%), 2006 6

Figure 3: Launch, core and expiry, absolute sales growth, 2006-12
(sales as % of 2006 sales), Genzyme 8

Figure 4: Launch, core and expiry, absolute sales growth, 2006-12
(sales as % of 2006 sales), peer set 9

Figure 5: Molecule type, externalization and geographic market
dependency (%) vs. peer set, 2006 11

Figure 6: Molecule type, externalization and geographic market
dependency (%) vs. peer set, 2012 12

Figure 7: SWOT analysis of Genzyme 15

Figure 8: Genzyme timeline 24

Figure 9: M&A/divestment history 25

Figure 10: Current corporate structure 29

Figure 11: Revenue & growth rate (ethical sales) ($m), 2001-06 34

Figure 12: Ethical revenue ($m) and growth rate (%) vs. peer set,
2001-06 37

Figure 13: Growth drivers/resistor products of historical revenue
performance ($m), 2001-06 39

Figure 14: Operating revenue/cost analysis ($m), 2001-06 42

Figure 15: Operating cost ratio analysis (% of total revenues),
2001-06 44

Figure 16: Ethical revenue ($m) and growth rate (%), 2006-12 46

Figure 17: Top five products by sales ($m), 2006 49

Figure 18: Top five products by sales ($m), 2012 50

Figure 19: Growth drivers and resistors by product, 2006-12 51

Figure 20: Key strategic products, sales ($m), 2006-12 53

Figure 21: Ethical sales by therapy area ($m), 2006-12 56

Figure 22: Growth drivers and resistors by therapy area ($m),
2006-12 57

Figure 23: Ethical sales by therapy area (%), 2006-12 59

Figure 24: Therapy area focus compared with peer set (% total
ethical sales), 2006 60

Figure 25: Therapy area focus compared with peer set (% total
ethical sales), 2012 61

Figure 26: Launch schedule, sales ($m), 2006-12 63

Figure 27: Core products sales growth ($m), 2006-12 65

Figure 28: Expiry schedule, sales ($m), 2006-12 66

Figure 29: Launch, core and expiry, sales ($m), 2006-12 67

Figure 30: Launch, core and expiry, absolute sales growth, 2006-12
(sales as % of 2006 sales), Genzyme 68

Figure 31: Launch, core and expiry, absolute sales growth, 2006-12
(sales as % of 2006 sales), peer set 69

Figure 32: Externalization dependency, sales ($m), 2006-12 71

Figure 33: Growth drivers and resistors, externally vs. internally
discovered products, sales ($m), 2006-12 72

Figure 34: Externalization dependency vs. peer set, % total sales,
2006 73

Figure 35: Externalization dependency vs. peer set, % total sales,
2012 74

Figure 36: Geographical sales breakdown ($m), 2006-12 75

Figure 37: Growth drivers and resistors by geography, sales ($m),
2006-12 76

Figure 38: US dependency vs. peer set, % total sales, 2006 77

Figure 39: US dependency vs. peer set, % total sales, 2012 78

Figure 40: Growth drivers and resistors by molecule type, sales
($m), 2006-12 80

Figure 41: Molecule type sales breakdown ($m), 2006-12 81

Figure 42: Biologics dependency vs. peer set, % total sales, 2006
82

Figure 43: Biologics dependency vs. peer set, % total sales, 2012
83

To order that report:

www.reportlinker.com/p073698
/Genzyme-Corporation-Company-Profile.html

(Due to its length, this URL may need to be copied/pasted into
your Internet browser's address field. Remove the extra space if one
exists.)

For more information, contact Nicolas by email
nbo@reportlinker.com , or by phone +33 4 37 65 17 03.

More market research reports?

Go to http://www.reportlinker.com

Reportlinker
Nicolas, +33 4 37 65 17 03
nbo@reportlinker.com

Copyright Business Wire 2008